Hypertensive disorders in pregnancy, experienced by 10 percent of women globally, are major contributors to maternal and newborn mortality, morbidity, and disability. Task shifting essential health services to mitigate insufficient human resources is recommended to strengthen and expand the health work force to rapidly increase access to quality services. Nigeria's task shifting policy recommends that community health extension workers administer a loading dose of magnesium sulphate prior to referral for severe preeclampsia or eclampsia to a higher level facility. The success achieved with magnesium sulphate task shifting to lower level health facilities has not been widely explored with anti-hypertensive drugs to control high blood pressure in pregnant women.
This study tested the feasibility and acceptability of community health extension workers at primary healthcare facilities in Ebonyi state to detect and manage pregnancy-associated hypertension using alpha methyldopa and magnesium sulphate where appropriate and refer for follow up. Baseline data were collected from 10 of 13 local government areas in 40 primary healthcare centers (20 interventions and 20 comparison) in 2016 and endline in November 2017.
In intervention arm only, community health extension workers were trained and mentored to detect, classify and manage hypertension associated with pregnancy, pre-eclampsia and eclampsia and refer to their affiliated secondary health facilities according to clinical protocols. For pregnant women identified with hypertension with or without significant proteinuria, they were recruited into the study and subsequently followed-up post-delivery. If a woman's blood pressure was not controlled, women were referred to a higher facility. For women with severe pre-eclampsia and eclampsia, they received a loading dose of magnesium sulphate and were referred.
Community health extension workers in the comparison arm received no training or mentorship; and continued with their usual practice of administering a loading dose of magnesium sulphate to women with severe pre-eclampsia/eclampsia and referral.
More community health extension workers in the intervention arm correctly identified normal blood pressure, and differentiated as well as managed, mild, moderate, and severe hypertension than those in the comparison arm. This included a 72 percent knowledge improvement in when to introduce antihypertensives versus a three percent improvement in the comparison arm; and were three times more likely to identify alpha methyldopa as a specific drug to control blood pressure at endline. Significant differences were also observed in knowledge and ability to categorize the various hypertensive disorders in pregnancy correctly. In both arms, community health extension workers were most likely to prescribe alpha methyldopa (60% and 50% respectively) at endline. Among women with moderate-to-severe hypertension who required anti-hypertensives upon diagnosis, more women in the intervention arm received treatment than women in the comparison arm.
During the study, five maternal deaths occurred: one intrapartum death from the intervention arm and four from the comparison arm (one antepartum, 2 intrapartum, one postpartum). The woman who died in the intervention arm did not receive a loading dose of Magnesium Sulphate following diagnosis of severe preeclampsia (all women who received a loading dose survived). A total of 13 fetal deaths also occurred: four in the intervention arm (3 stillbirths and one early neonatal death) and nine to the comparison arm (all stillbirths). None of the mothers of the babies who died received a loading dose of magnesium sulfate.
Community health extension workers at primary health care facilities can correctly measure blood pressure, detect abnormal blood pressure, and treat accordingly for severe pre-eclampsia and eclampsia, and refer to a higher facility for further management. Although challenges remain in ensuring sufficient commodities and supplies are continuously available, this study demonstrates how ministries of Health might use these missed opportunities to detect pre-eclampsia (and potentially other conditions) and prevent deterioration by providing anti-hypertensives and magnesium sulphate to stabilize and refer women.
BACKGROUND
Hypertensive disorders in pregnancy (HDPs), experienced by 10 percent of women globally, are major contributors to maternal and newborn mortality, morbidity, and disability 1-2 . HDPs include pre-eclampsia, gestational hypertension (hypertension), and chronic hypertension during pregnancy. Pre-eclampsia, defined as hypertension with significant proteinuria after 20 weeks' gestation in pregnancy, complicates two to eight percent of pregnancies 3, 4 . In low-and middle-income countries (LMICs), a woman is seven times more likely to develop pre-eclampsia than a woman in a high income country. Some 10 percent to 25 percent of women who suffer from pre-eclampsia likely will die 5, 6 . About 10 percent of women with preeclampsia develop severe pre-eclampsia and eclampsia [6] [7] . Of the 10 to 25 percent of the pre-eclampsia and eclampsia (PE/E)-related maternal deaths worldwide, eclampsia accounts for about 14 percent 5, 8 .
In recent years, there has been increased recognition and support for the use of magnesium sulphate (MgSO4) as a life-saving and cost-effective maternal health commodity, both as prophylaxis and treatment for convulsions due to severe PE/E [9] [10] [11] [12] [13] [14] [15] [16] [17] . Similar attention has not been given to identifying and managing hypertension associated with PE/E, as well as other forms of hypertension seen in pregnancy. Failure to address hypertension minimizes the gains in institutionalizing MgSO4 in a health system for PE/E management.
Globally, task shifting essential health services to accommodate insufficient human resources is recommended for strengthening and expanding health workforces for rapid increases in access to quality services [18] [19] . Specific reorganization and decentralization recommended by the World Health Organization (WHO) is due to the knowledge that lower level cadres such as auxiliary nurse and midwives can administer, with targeted monitoring and evaluation (M&E), anti-hypertensive drugs for severe HDP 19 . Less, however, is known about the abilities of community health extension workers-the main figures in primary health care (PHC) in Nigeria-and their suitability to provide anti-hypertensive services. CHEWs are a lower level service provider cadre with more training than an auxiliary nurse or midwife (as defined by WHO).
CHEWs in Nigeria receive three years of pre-service training and community experience, so it is conceivable they could also be provided with appropriate knowledge, skills, and training for managing moderate and severe hypertension using anti-hypertensive drugs recommended for use in pregnancy, and then referring women to higher levels for follow up care, if appropriate.
In Nigeria, HDPs-principally PE/E-account for over 23 percent of deaths among pregnant women 6 . Programs for averting PE/E mortality and morbidity have made MgSO4 routinely available, with some success 9, 11, 20 . These efforts have also implemented task shifting for CHEW administration of a loading dose of MgSO4 prior to referrals to a higher level facility for severe PE/E [20] [21] . The successes achieved with MgSO4 task shifting to lower level health facilities has not been widely transferred to anti-hypertensive drugs for controlling high blood pressure (BP) in pregnant women prior to referral.
Rapidly increasing BP may result in cerebrovascular accident (CVA), a known cause of death in women with PE/E. Addressing HDP in a timely and effective way reduces maternal morbidity and mortality, but emphasis has varied on how to achieve this goal, with more attention to MgSO4 and less emphasis on studying the administration of anti-hypertensive drugs 21 . Before 2013 in Nigeria, CHEWs at PHCs were not authorized to administer MgSO4 for severe PE/E due to perceptions of insufficient training 22 . A quasi-experimental pilot study in Kano state showed that MgSO4 task shifting (initial dose for women with severe PE/E, and referral to secondary hospitals) to CHEWs at PHCs resulted in demonstrable improvements in maternal and neonatal survival 20 . The study trained CHEWs, with one year of follow up, M&E, and supportive supervision. Presentation of these findings at the 2012 National Council of Health (NCH) of Nigeria contributed to the policy change allowing CHEWs to administer a loading dose of MgSO4 prior to referral.
Although HDP treatment by PHC CHEWs is not recommended in Nigeria's current national task shifting policy, a 2015 analysis in seven Nigerian states, of service providers' knowledge and practices, and pregnant women's and community members' understanding, of PE/E found that 41 percent of PHC providers (mainly CHEWs) reported prescribing anti-hypertensive drugs-some not recommended in pregnancy-to pregnant women 23 . It is imperative to provide appropriate anti-hypertensive drugs to pregnant women with moderate to severe HDP, and at their first contact with the health system.
CHEWs are currently not authorized to prescribe anti-hypertensive drugs but can refer pregnant women with high BP to a secondary hospital, although they may have the capacities to treat women on site 21 . This is contrary to other countries' practices and WHO recommendations for task shifting to lower level cadres [18] [19] . This study tested the feasibility and acceptability of Nigeria's PHC CHEWs to detect and manage HDP using alpha methyldopa, including administration of MgSO4 and referral to higher level care, where appropriate.
STUDY GOALS AND OBJECTIVES
The overall aim of this study was to assess the feasibility and acceptability of CHEWs' detection and management of HDP using alpha methyldopa. The specific objectives were to:
 Assess the feasibility of CHEWs' detection and classification of high BP among pregnant women during antenatal care (ANC) contacts,  Assess CHEWs' abilities to prescribe an anti-hypertensive drug (alpha methyldopa) for pregnant women with moderate hypertension, and  Assess CHEWs' abilities to prescribe appropriate an anti-hypertensives drug (alpha methyldopa) for pregnant women with severe hypertension during PE/E prior to referral, including prescribing and administering MgSO4 for severe PE/E prior to referral.
METHODOLOGY STUDY SETTING
This study was conducted in southeastern Nigeria's Ebonyi state, comprised of 13 local government areas (LGAs). Ebonyi is one of the three states where Population Council implemented the Ending Eclampsia project, a larger effort supporting PE/E prevention, early detection, and management at lower health system levels 23 . Ebonyi has the worst health indices among Nigeria's southeastern states, similar to many northern states; but its level of education is generally higher than the north, which makes Ebonyi a conducive setting for this study. 
HOW INTERVENTIONS WERE OPERATIONALIZED
PHC CHEWs were trained and mentored by this study to detect, classify, and manage HDP, including referring patients to affiliated secondary hospitals. Hypertensive disorders investigated included chronic hypertension (defined as isolated hypertension diagnosed before the index pregnancy or detected before 20 weeks of gestation), gestational hypertension (isolated hypertension diagnosed for the first time after 20 weeks of index pregnancy without proteinuria), and pre-eclampsia (gestational hypertension and proteinuria of ≥ ++ using a urine dipstick). Hypertension was defined as a systolic BP (sBP) of ≥140mmHg and or diastolic BP (dBP) of ≥90mmHg measured on two different occasions, four to six hours apart. In some cases, where distance was a factor, clients stayed at the facility for repeat measurement; if clients lived nearby, they were instructed to return.
CHEWs were trained and mentored to correctly diagnose hypertension as chronic, gestational, or as PE/E. Training also featured hypertension classification-as mild, moderate, or severe-and either pre-eclampsia or severe pre-eclampsia. For mild hypertension, CHEWs were trained to only regularly monitor BP. For moderate hypertension, CHEWs prescribe alpha methyldopa. For severe hypertension, in addition to continued alpha methyldopa, CHEWs were advised to refer clients to a higher level facility, and if associated with severe pre-eclampsia, CHEWs administered a loading dose of MgSO4 before referral (see Table 1 ).
FACILITY SELECTION AND CHEWS IDENTIFICATION AND TRAINING
In collaboration with Ebonyi state's Ministry of Health (SMoH), Ending Eclampsia randomly selected 10
LGAs: five (featuring 20 PHC facilities) to serve as intervention sites and the other five (also with 20 PHCs) as comparison sites. Both the intervention and comparison arms were already trained and authorized to administer a loading dose of MgSO4 for severe PE/E. CHEWs conducting antenatal care (ANC) services in the intervention arm were then also trained to detect and classify HDP, including treatment with alpha methyldopa and a loading dose of MgSO4, when appropriate. CHEWs in the comparison arm received no such training and mentorship, and were to continue usual practice, which includes administering a loading dose of MgSO4 to women with severe PE/E, as recommended by the national task shifting policy, for referring women with high BP during pregnancy. In October 2016, CHEWs in the intervention arm attended a three day, competency-based training workshop. A group of master trainers (MTs) and trainers selected from SMoH and Ob/Gyn and midwifery professionals was established. Pre-and post-training tests assessed immediate changes in knowledge. The training curriculum was based upon WHO as well as the national guidelines for HDP management 24 .
E B O N Y I S T A T E , N I G E R I A
Treatment protocols and a referral decision-making tree for HDPs (also developed based upon WHO recommendations) were provided to CHEWs, to guide identification and treatment for women with HDPs. The protocol and decision-making tree describe ways to identify HDP during ANC (and PNC) and to categorize hypertension as chronic, gestational, or as pre-eclampsia. Furthermore, the guidelines provide information for grading hypertension as mild, moderate, and severe, and management of each category. Training also emphasized how to correctly determine BP, conduct urine protein testing with dipstick, and when to administer anti-hypertensive drugs (alpha methyldopa, Aldomet), as well as counseling clients and referral processes. CHEWs were also instructed how to document the essential elements of their ANC services, for example BP and urine results, past medical history, gestational age, and identifying danger signs and symptoms in pregnancy. Details of counseling and referral, including policy guidelines for referral and the importance of adherence to referral, were emphasized. CHEWs were also oriented on the study procedures, ethical issues, as well as the participant enrollment processes.
CHEWs in the comparison arm did not receive any training on HDP detection and management (other than standard CHEW services in Nigeria, which includes administering a loading dose of MgSO4 to women with severe PE/E, and referral).
CHEWs' training on HDP diagnosis, classification, and management was based upon the algorithm shown in Table 1 7 Figure 1 : Flow chart for diagnosing and managing hypertension in pregnancy for this study Figure 1 : Flow chart for diagnosing and management NTN in pregnancy for the study
CLIENT IDENTIFICATION
Pregnant women attending an ANC clinic were screened for hypertension and proteinuria. For women with high BP or significant proteinuria, CHEWs documented their socio-demographic characteristics, obtained informed consent, and recruited them into the study. Only hypertensive pregnant women 15 years or older were enrolled. Although the age of consent in Nigeria is 18 years, pregnant women younger than 18 are considered emancipated by virtue of their pregnancy status. And in addition, the national policy for research with adolescents indicates that adolescents can make informed decisions about their medical needs 25 .
CHEWs opened a treatment folder for each client, in which all clinical decisions and medical interventions were documented. Each recruited client was followed until her delivery, and into the immediate postpartum period (up to 48 hours) to determine if she was managed according to the guidelines. Permission for a follow up call was obtained during the informed consent process.
CLIENT REFERRAL
Guided by the decision-making tree (job aid and treatment algorithm, see Figure 1 ), if a woman's BP was not controlled, she was referred to a physician at a secondary-or higher level facility. When a woman had severe PE/E, she was administered a loading dose of MgSO4, according to the national standard, and referred to a higher level facility for definitive management. CHEWs displayed job aids in their consultation, treatment, and labor rooms for ease of reference.
To track referrals, CHEWs issued a duplicate copy of a client's completed case notes for the client to take to the referral facility; then, if a client did not present at a referral facility, the CHEW called the client or her family directly. In the comparison arm, CHEWs were encouraged to refer clients with severe cases to higher level facilities for definitive management, but they did not receive training on how to identify and manage HDPs.
SUPPLY OF ANTI-HYPERTENSIVE DRUGS (ALPHA METHYLDOPA)
Before commencing the study, consultative meetings with Ebonyi SMoH requested their procurement, supply, and monitoring of uptake of anti-hypertensive drugs (alpha methyldopa only) among the study's intervention facilities, staff, and clients. Initial doses of alpha methyldopa were prescribed by CHEWs and obtained from facilities' pharmacies. If stock outs occurred during the study, clients were asked to obtain the drug at a local pharmacy (while efforts were being made to replenish facility supplies). Women were instructed to return for prescription refills at the health facility; BP was re-checked at every visit.
CHEW SUPPORTIVE SUPERVISION AND JOB AIDS
Chews were monitored and mentored monthly, and clients' records were reviewed during each monitoring visit to ensure chew compliance with ethical and clinical standards. This monthly supportive supervision was in collaboration with Ebonyi SMoH. A SMoH physician provided M&E and supervision for the management of any adverse events of drugs. During supportive supervision visits, chews were observed for how they measured and determined BP and tested for urine proteins. In instances with no incidences of hypertension at a facility, chews were encouraged to explain the HDP treatment protocol and algorithm ( Figure 1 ).
SAMPLING, DATA COLLECTION AND ANALYSIS
The study's design was quasi-experimental and a non-equivalent comparison, in which 40 PHC facilities from 10 LGAs were divided into two arms (5 LGAs in each arm)-experimental and comparison. Four PHC facilities were selected within each, LGA for a total of 20 facilities per study arm. There were three periods of data collection during implementation-at baseline in October 2016, immediate post-training in November 2016, and endline in November 2017.
At baseline, a cross-sectional survey of health care providers' (mainly CHEWs) knowledge and practices was conducted in both study arms using a pre-tested, interviewer-administered questionnaire (October 2016). At the same time, a facility inventory determined availability of commodities and supplies for HDP detection and management. Quarterly facility inventory reviews were conducted throughout the intervention period in the intervention arm.
After CHEWs in the intervention arm were trained on HDP detection and management in November 2016, a post-training test determined any change in their knowledge of HDPs.
At endline, in November 2017, a provider survey of the trained CHEWs arm assessed their knowledge retention. All case notes from enrolled clients were retrieved and reviewed to determine how clients were identified, classified, and managed, in addition to the quality of care provided by CHEWs.
Lastly, in November 2017 in-depth interviews (IDIs) with women diagnosed with HDPs helped to understand their experiences and perceptions of their care from CHEWs, including their perceptions of their pregnancy outcomes. Table 2 charts the data collected at baseline and endline. 
DATA MANAGEMENT AND ANALYSIS
All completed questionnaires were transferred immediately to the Council's Abuja office for data entry and analysis. All hard copies of questionnaires, consent forms, and client case notes were sealed and stored in secured, locked drawers at the Council office. They will be stored for five years before being destroyed.
Data were analyzed with STATA, presented in frequency tables. To answer "Are lower level service providers able to identify, classify, and manage hypertensive disorders in pregnant women and manage appropriately with alpha methyldopa?", a chi-square/Fisher's exact test determined associations among categorical variables. A non-linear difference in difference analysis determined the intervention's effects while accounting for baseline differences. P-values <0.05 are considered statistically significant.
Outcomes such as how well HDP was controlled, CVA incidence, and maternal and fetal survival were assessed. Analysis considered whether CHEWs correctly diagnosed and categorized HDPs, as well as women's gestation at initial ANC, diagnosis, and study enrolment. Women diagnosed with moderate hypertension and severe PE/E were interviewed to ascertain whether they received anti-hypertensive drugs and MgS04, as appropriate. Women referred to higher facilities for definitive management were reported upon, and women's gestation at delivery, fetal and maternal outcomes were determined.
To evaluate clients' quality of care, tests of association were conducted, looking closely at client case notes. Qualitative data from IDIs with women who experienced PE/E were digitally recorded, transcribed, translated, and analyzed to understand women's perspectives about their quality of care from CHEWs at PHCs as well as at referral facilities. Enrolled women's information was documented by CHEWs, including telephone number and community name, for ease of follow up. A doctor of medicine from SMoH provided quality control and followed up on any adverse and serious adverse events during the study.
ETHICAL REVIEW AND CONSENT

RESULTS
The key findings from this intervention include the experiences and perspectives of clients enrolled in the study. Table 3 describes basic the characteristics of participating CHEWs at both the intervention and control PHCs, at baseline and endline. There were no significant socio-demographic differences between the two arms, but their differences in work experience neared significance (P=0.05). Table 4 on the preceding page shows that the training's implementation was followed by a change in CHEWs' knowledge and ability to manage HDPs. Table 5 shows that CHEWs in the intervention arm had improved knowledge and abilities to distinguish PE/E from other forms of hypertension than those in the comparison arm. In both the intervention and comparison arms, CHEWs mostly identified alpha methyldopa and Nifedipine as the drug of choice for controlling BP (Table 6 ). In addition, alpha methyldopa was the most prescribed anti-hypertensive drug in both arms, however, prescription of this drug did not differ between the intervention and control arms. At endline, almost no CHEW in either arm prescribed hydralazine, despite intervention CHEWs' awareness of it as a drug used to control BP. 
MANAGEMENT OF WOMEN WITH HYPERTENSION IN PREGNANCY
There were no significant differences between the two study arms in gestational age at booking or gestational age at diagnosis. We found a difference in gestational age at delivery between the two study arms (P=0.02), but this difference may be due to the fewer women in the comparison arm (n=14). Following CHEWs' training, only one client seen at an intervention PHC center was mis-classified for HDP and its severity. By contrast, CHEWs in the comparison arm misclassified nine women (see Table 8 , following page).
Among women with moderate to severe hypertension requiring anti-hypertensive drugs upon diagnosis, more women in the intervention arm received treatment (p<0.001). Furthermore, 50 percent of women with severe pre-eclampsia in the intervention arm received a loading dose of MgSO4 upon diagnosis, while no woman in the comparison arm received a MgSO4 loading dose (Table 8) .
During this study's duration, a total of five maternal deaths occurred-one in the intervention arm (intrapartum death) and four in the comparison arm (one antepartum, 2 intrapartum, one postpartum). The woman who died in the intervention arm did not receive a loading dose of MgSO4 after her diagnosis of severe pre-eclampsia; all women who received a loading dose survived. A total of 13 fetal deaths also occurred: four in the intervention arm (3 stillbirths, one early neonatal death) and nine in the comparison arm (all stillbirths). No mothers of the infants who died received a loading dose of MgSO4.
These maternal and perinatal deaths were due to a combination of MgSO4 unavailability at facilities, at the time of diagnosis of severe PE/E, and client failures to complete the referral process-and not receive the drug. Upon study recruitment (immediately after diagnosis), only four women were given anti-hypertensive drugs in the comparison arm, yet 29 in the intervention arm were. Similarly, of the women diagnosed with severe PE/E at recruitment, only nine women were given MgSO4 (2 in the comparison arm and 7 in the intervention arm). 
FACILITY STOCK REVIEWS
A pre-post assessment of the 20 facilities from the comparison and intervention arms determined monthly availability of commodities for effective HDP management (figures 2 and 3) over the implementation period (December 2016 to November 2017). When Ending Eclampsia activities started in June 2016, stocks of key supplies was generally poor (Figure 2 ). Most Ending Eclampsia facilities had no anti-hypertensive drugs, calcium gluconate, urine test strips, etc. The project encouraged-and had impact upon-the stocking of such commodities (Figure 2 ).
An industrial action (or workers' strike) in June 2017 lasting about two weeks, an effort of the Joint Health Sector Union (JOHESU-minus doctors) in Nigeria, lead to reduced supply availability. JOHESU is the largest umbrella of the health workforce, therefore any attempt of industrial action can result in total facility closures, leading to an inability for SMoH or Central Medical Stores to supply commodities. Consequently, when the team visited to collect data during that period, not all facilities had resumed operation, despite the resolution of the union to resume work.
Importantly, this period (June and July 2017) was characterized by extensive and massive health provider transfers due to the introduction of PHCUOR (Primary Health Care Under One Roof policy) in Ebonyi, causing another reduction in equipment and commodity availability. Some BP machines were not the property of facilities but "privately owned," and left when staff were transferred. In addition, from June until November 2017, some facilities reported damaged BP machines, which contributed to the reduced availability of functional BP machines.
While all facilities had functional BP machines at baseline, there was a decline in their availability at endline. Although stocks of urine test strips, calcium gluconate, MgS04, and anti-hypertensive drugs increased, the trend indicates not all facilities consistently stocked these commodities and supplies. MgS04 appeared to expire more frequently at facilities in the comparison arm, especially at baseline. 
CLIENT ATTENDANCE AND SERVICES
More women attended facilities for ANC in the intervention arm (figures 4 and 5). Not every woman received BP measurement or urine tests at each visit, although national standards stipulate that every woman should be screened at every visit. Following the intervention, more women had BP and urine checked during ANC visits than pre-intervention, and this consistently increased overtime: At first ANC visit, 94 percent of women had BP measured, while 85 percent had a urine test. Figure 4 shows that total BP measurement was slightly higher than total urine tested. Average monthly BP measurement was 177 (standard deviation 57.5) and average monthly urine testing was 137 (standard deviation 71.8). 
WHAT DO WOMEN KNOW ABOUT HYPERTENSION IN PREGNANCY?
Women's understanding and perceptions of HDP varied. Some thought that there are specific symptoms that might provoke them to consider they had high BP. Even when symptoms occur (headaches, dizziness) women tend to ascribe the symptoms to more familiar health conditions such as malaria in pregnancy.
"I felt it was malaria that I was having, and I started taking malaria drugs and after taking it, it did not stop so I went to the health center where I registered for antenatal care, and they checked me and told me that what I am suffering from is not malaria, but it is high blood pressure that I am suffering from." HPD survivor, 22 years of age, multigravida, intervention arm Some women could not recognize the onset of their hypertension, while some only realized it after they were told by their health providers. 
WOMEN'S PERCEPTIONS OF THE CONTENT OF THEIR CARE
Generally, but especially in intervention communities, women reported high satisfaction and favorable opinions of their providers' attitudes, both for them and their care. Overall, women in the intervention arm reported improved care experiences, and many women seen at intervention facilities believe their care was adequate. In both arms, women felt respected by their care providers, both at PHC and referral facilities.
"[The care provider] was very careful giving me blood pressure drugs when I come. Those health providers used to take good care of me, if I come, they will start calling me with sweet names and they use to play with me, they have good attitude towards me." HDP survivor, age 35, multigravida, intervention arm "You know, the health provider that attended to me lives in our community, even though she's not originally from here; but she interacts with us very well, so when we come for antenatal care visits, she treats us kindly to make us happy." HDP survivor, age 23, primigravida, comparison arm
This project used health talks and communication to improve women's knowledge of important pregnancy issues and empowered women to ask questions around their health and on any clinical and laboratory findings. Similarly, women also reported increased communication between them and their care providers. Women received health talks on their necessary health services and actions they should take in cases of abnormal results.
"They used to give us health talks on different topics. What they teach today is not what they will teach tomorrow, and that is the first thing they do before conducting health checks on us." HDP survivor, age 28, multigravida, comparison arm Women in the intervention arm reported better prescription practices than those in the comparison arm. Some women received appropriate anti-hypertensive drugs but did not know specifics about dosages or frequency, and some felt it was usual for health care providers to not provide prescription specifics. Women also complained that CHEWs sometimes instruct them to purchase their anti-hypertensive drugs from outside sources due to lack of drug availability at facilities: Women from both study arms failed to complete their referral process due to lack of detail and discussion at their originating PHCs on the reasons for their referrals. These gaps in communication lead to declines and non-adherence within the referral process. Some women complained of lack of financial reserves for transportation to referral centers. CHEWs sometimes do not refer women to facilities closest to them. Women often resort to borrowing to enable travel to referral centers.
"I usually enter okada [motorcycle] from Ogwor to Afikpo, I will say that it is far, as someone who has nothing doing…we are just managing our best, we struggle to eat, he [husband] is trying his best, anytime they said come, he will try to make sure that I go even if it means borrowing, he will do so to ensure that I went." HDP survivor, age 30, multigravida, intervention arm
Sometimes women refused the recommended means of care. Some women were recommended for hospital admission, but insisted on returning home due to lack of finances. Financial burdens are a significant factor in whether women adhere to prescribed care (including referrals).
"When I got to Afikpo, they found out that I have high blood pressure. They said that they will give me bedrest, I told them to allow me to go and look for money. 
LATE ANTENATAL CARE REGISTRATION AND INCONSISTENT CONTACT IMPAIR EARLY DETECTION AND MANAGEMENT OF HYPERTENSION IN PREGNANCY
Late ANC registration is still common. Generally, pregnant women's first ANC contact is after 20 weeks' gestation-in both study groups. Women also appear to simultaneously register in at least two facilities for ANC. In some cases, women were already having complications by the time of their initial ANC at a facility:
"I know that I did not start antenatal on time. It was when I started feeling somehow [abnormal] that my husband insisted that I should go to the maternity and register. By that time, I was six months pregnant." HDP survivor, age 30, primigravida, comparison arm
In addition to registering for ANC at multiple facilities, women may also seek care from religious groups or traditional birth attendants, due to pressure from friends and family.
"I went to the tradition medicine when I was pregnant, you know that if you have problem, many people will be suggesting and advising you to go here or there, you will continue to move from one place to another." HDP survivor, age 38, multigravida, comparison arm "Let me tell you, I came here [PHC center] to confirm my pregnancy, and that was at 18 weeks, but I'm used to receiving treatment at Mama Mgbo [a traditional birth attendant]." HDP survivor, age 38, multigravida, comparison arm DISCUSSION Given HDPs' contribution to maternal and perinatal deaths in Nigeria 1-2, 6 , coupled with the increasing recognition that providers at lower levels (such as PHC) of the health system are a vital point of care for women and children, this project aimed to test the feasibility of CHEWs to detect and manage HDP using alpha methyldopa, as well as MgSO4 administration and referral in selected cases.
This study shows that CHEWs in the intervention sites were able to correctly measure BP and manage HDP. CHEWs at intervention PHC centers were 60 percent more likely to correctly grade hypertension as mild, moderate, or severe, an essential step for effective HDP management of women seeking lower level health care. Those CHEWs were also better able to differentiate HDPs as chronic hypertension, gestational hypertension, or pre-eclampsia. More women attended ANC in the intervention arm, but their BP was not measured, nor urine tested, at every contact. While in resource-poor environments only testing urine for proteinuria for BP over 140/90 may be understandable, there should be no excuse for not measuring BP at every contact. A recent study of facility readiness in sub-Saharan Africa showed particularly poor abilities to manage HDP, indicating that measurement of BP alone may not be adequate for quality care, however 26 .
CHEWs at intervention PHCs also appropriately prescribed alpha methyldopa to pregnant women with moderately severe hypertension. Essential maternal health commodities such as MgSO4 and urine dipstick were more frequently available at intervention facilities, indicating that the intervention affected and improved the supply chain and logistics system. Although facilities in the comparison arm (as are all PHCs in Nigeria) were already mandated by the national task shifting policy to provide a loading dose of MgSO4 and other basic obstetrics services, this intervention has demonstrated that it is possible to integrate an additional service to more holistically manage women with HDPs.
CHEWs' MgSO4 knowledge and use, for women with severe PE/E, improved by 55 percent. Half of all women managed at intervention facilities were administered a loading dose of MgSO4, as opposed to none at comparison sites. This provides the needed evidence and support to begin the empowerment of CHEWs to provide these services more broadly at the PHC level in Nigeria, and in other places with a similar health system structure. A similar study in Nigeria supports CHEW provision of a loading dose of MgSO4 to women with severe PE/E 8, 11 .
Maternal and perinatal outcomes were better among women managed at intervention PHCs. The sample sizes in both study groups (40 and 14 women, respectively) were too small for firm conclusions, but these results show potential for this sort of PHC intervention. Where provider skills are enhanced, and essential commodities become more available, health outcomes will consequently improve, as seen in this study, and demonstrated in others [27] [28] [29] .
Women's perceptions and experience of their use of PHC services were very encouraging. Women maintain favorable opinions and that their CHEWs provided adequate information, through health talks on various ANC issues, with cordiality by their providers 30 . CHEWs must, however, improve their communication of critical information to clients, to accurately convey clients' severity of condition to them. In some instances CHEWs did not provide adequate information on use of drugs supplied or prescribed. Some women also felt that CHEWs "concealed information" from them about their diagnoses, possibly due to the belief their clients were better not knowing about their condition severity. If women and their families do not know or understand how serious their medical conditions are, and their potential consequences, they may be less likely to urgently seek care.
Local and state governments must fulfill their responsibilities for ensuring essential tools and commodities are available-both at their points of need, and at all times.
